Cell lineage as a predictor of immune response in neuroblastoma
Official title: Cell lineage as an indicator of immune response in neuroblastoma
Funded at Dana-Farber Cancer Inst · NIH-11323558 · Data updated 2026-11-12
Researchers are exploring how the cell type of a child’s neuroblastoma tumor may determine how well immune-based therapies work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 16, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $405,378 |
| NIH project number | 5R01CA271605-05 |
| Project ID | NIH-11323558 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children with neuroblastoma whose tumors exhibit mesenchymal-like or adrenergic cell lineage states may be most relevant for future applications of this work.
✕Less likely to help
Patients whose tumors do not show the studied lineage differences may have less direct benefit from the findings.
What this research studies
This project looks at how different cell lineages within pediatric neuroblastoma tumors influence the effectiveness of immune-based treatments. By analyzing a large dataset of tumor gene activity, the team identifies mesenchymal-like tumors that may respond more to immune therapies and adrenergic (ADR) neuron-like tumors that tend to be less responsive. The work seeks to map immune signaling patterns to tumor cell states and test whether lineage state can predict treatment outcomes. The ultimate goal is to guide more personalized immunotherapy strategies for children with neuroblastoma.
Why it matters
Potential benefit: If successful, this research could help tailor immunotherapy approaches to a child’s tumor cell state, potentially improving response rates and outcomes.
How similar studies have gone: Previous work has linked tumor cell states to immunogenicity in neuroblastoma, with promising signals that lineage state can influence therapy response.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: George, Rani E. — Dana-Farber Cancer Inst
- Study coordinator: George, Rani E.
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.